mNEXSPIKE 0.05 mg/mL
As listed in the register: mNEXSPIKE 0.05 mg/mL, Injektionsdispersion
0.05 mg/mL ·
- Prescription only
- Antibiotics, antivirals and antifungals taken into the body
- Active substance
- SARS-CoV-2 XBB.1.5 mRNA
- Made by
- Moderna Switzerland GmbH
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- mNEXSPIKE wird angewendet zur aktiven Immunisierung von Personen ab 12 Jahren zur Vorbeugung von COVID-19, verursacht durch SARS CoV 2
From the official label · 2026-09-30 · Swissmedic
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
European UnionNo exact match for this strength and form
SpainNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
Details
| Made by | Moderna Switzerland GmbH |
|---|---|
| Active substance | SARS-CoV-2 XBB.1.5 mRNA |
| Used in | Antibiotics, antivirals and antifungals taken into the body |
| Strength | 0.05 mg/mL |
| Classification | J07BN01 · Antibiotics, antivirals and antifungals taken into the body |
| Dispensing (as stated by the register) | Abgabekategorie B |
| Name in the register | mNEXSPIKE 0.05 mg/mL, Injektionsdispersion |
| Packs | 1 Fertigspritze(n) · 10 Fertigspritze(n) |
| Zulassungsnummer | 70272 |
| Dosisstärke | 1 |
Source: Zugelassene Packungen Humanarzneimittel · 2026-09-30 · not reviewed by a clinician
Quelle: Swissmedic. The publisher’s terms do not grant reproduction, so text is shortened and linked. Publisher’s terms.